Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of pegfilgrastim prophylaxis for chemotherapy-induced neutropenia in breast cancer
ChiCTR1900021399Phase 4Not yet recruiting
- Sponsor
- Tianjin Medical University Cancer Institute and Hospital
- Start
- Mar 2019
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of pegfilgrastim in breast cancer, sponsored by Tianjin Medical University Cancer Institute and Hospital. Primary endpoints: Febrile neutropenia incidence and Occurrence and severity of adverse reactions. Planned start Mar 2019; status: not yet recruiting.
02
Drugs
pegfilgrastim
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR1900021399.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900021399.